# Zeo ScientifiX, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Zeo ScientifiX, Inc.). ## Overview Zeo ScientifiX, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on biological therapeutics for degenerative diseases and regenerative medicine. Its portfolio includes products derived from ethically sourced birth tissue, amniotic fluid, exosomes, Wharton's Jelly matrix, and an autologous biologic platform, with operations centered on manufacturing, commercialization, and related clinical support services. ## Products & services • Zofin™ amniotic-fluid derived biologic • Patient Pure X™ (PPX™) autologous biologic service • Allogenic aesthetic biologic products • Stem cell and exosome-derived biologics • cGMP manufacturing and quality control release testing • Market access, distribution, and clinical site support - **Biologic therapeutics** (69%) — Proprietary biologic products derived from birth tissue, amniotic fluid, and related sources. - **Autologous biologic services** (29%) — Patient-specific PPX™ processing and service platform using a patient's own blood. - **Manufacturing and quality services** (2%) — cGMP production, release testing, and related laboratory support for biologic products. - Zofin™ amniotic-fluid derived biologic - Patient Pure X™ (PPX™) autologous biologic service - Allogenic aesthetic biologic products - Stem cell and exosome-derived biologics - cGMP manufacturing and quality control release testing - Market access, distribution, and clinical site support ## Customers Zeo ScientifiX sells primarily to healthcare providers, including doctors and clinics that administer regenerative medicine and aesthetic biologic products. Its commercial model also depends on distributors and, in collaboration settings, clinical and manufacturing partners that support product access and delivery. - **Healthcare providers** (primary) — Doctors, clinics, and treatment centers that purchase biologics for in-office use and patient care. - **Regenerative medicine practices** (primary) — Providers focused on degenerative disease, wound care, pain, and regenerative applications. - **Aesthetic medicine providers** (secondary) — Clinics using allogenic aesthetic biologic products for cosmetic and related procedures. - **Independent distributors** (secondary) — Channel partners that market and distribute the company's products to providers. - **Clinical collaboration partners** (emerging) — Partners involved in manufacturing, regulatory development, and site management for specific programs. - Physicians and clinics buying biologics for patient administration - Regenerative medicine providers seeking tissue-derived therapies - Aesthetic medicine practices using allogenic biologic products - Distributors that extend market reach across the U.S. - Clinical partners needing manufacturing and site-management support ## Geography The company is headquartered in Davie, Florida and operates through U.S.-based laboratory and commercial activities. Its disclosures indicate a customer and distribution network across the United States, with additional worldwide reach through its broader provider base and collaboration activity. - **United States** (100%) — No country-level revenue table was disclosed; company states U.S. and worldwide customer reach. - Headquartered in Davie, Florida - U.S. commercial activity is central to the business model - Manufacturing and lab operations are FDA-registered and cGMP-compliant - Customer and distribution network spans the United States - Disclosures also reference worldwide provider reach ## Strategy Zeo ScientifiX is focused on expanding commercialization of its biologic portfolio while continuing product development and clinical work in regenerative medicine. The company also appears to be building channel reach through in-house sales, distributors, and collaboration-based manufacturing and market-access arrangements. - **Expand provider commercialization** (short-term) — The business depends on provider adoption and repeat use of its biologic products. - **Develop new biologic offerings** (medium-term) — New products can broaden the addressable market and reduce reliance on a narrow product mix. - **Strengthen collaboration-based execution** (medium-term) — Partnerships can provide manufacturing capacity, regulatory support, and commercial reach. - Expand sales to healthcare providers through direct and distributor channels - Broaden the product line with new regenerative medicine offerings - Support clinical development and regulatory compliance for biologics - Use collaboration structures to add manufacturing and market access - Increase training and education for provider adoption ## Risks The company faces substantial going-concern, funding, and execution risk because its business requires ongoing capital, regulatory compliance, and successful commercialization of biologic products. It also operates in a competitive and highly regulated regenerative medicine market where product acceptance, intellectual property protection, and supply continuity can materially affect results. - **Going-concern and financing dependence** [critical] — Operations and development require additional capital, and funding may be costly or unavailable. - **Regulatory and compliance risk** [high] — Products are biologics subject to FDA oversight, HCT/P enforcement, and cGMP requirements. - **Competitive pressure** [high] — Larger competitors may have stronger brands, capital, and distribution, pressuring pricing and share. - **Supply concentration and third-party dependence** [medium] — Raw materials and supplies are sourced from unaffiliated laboratories and could be disrupted. - **Intellectual property protection** [medium] — Commercial success depends on patents and proprietary processing techniques. - **Internal control weaknesses** [high] — Material weaknesses can impair financial reporting reliability and investor confidence. - Going-concern risk and dependence on external funding - Regulatory risk tied to FDA and HCT/P compliance - Competition from better-capitalized regenerative medicine firms - Supply-chain risk from third-party raw material sources - Intellectual property risk for proprietary biologics and processes - Internal control weaknesses can affect reporting reliability ## Accounting Revenue recognition depends on the mix of product sales and PPX™ service activity, which can shift reported margins and comparability across periods. Investors should also watch stock-based compensation, laboratory-related costs, and estimates tied to going-concern assessments, impairment, and internal control remediation because these judgments can materially affect reported results and balance-sheet values. - **Revenue recognition by product vs. service** — Affects revenue timing, gross margin, and comparability - **Stock-based compensation** — Can materially increase operating expenses - **Going-concern and asset recoverability** — May lead to impairment or write-down risk - **Internal control and disclosure estimates** — Affects reliability of financial statements - Revenue mix between product sales and PPX™ services affects margins - Stock-based compensation can materially affect G&A expense - Going-concern judgments influence asset recoverability assumptions - Inventory and supply costs matter for biologic product gross margin - Internal control weaknesses raise reporting and estimate risk --- *Last updated: 2026-04-29T05:11:40.715828+00:00*